Roche’s Perjeta regimen helped people with HER2-positive early breast cancer live longer without their disease returning or getting worse compared to Herceptin and chemotherapy New data from Phase II NeoSphere study provide additional evidence on the role of Perjeta in the neoadjuvant (pre-surgery) treatment of HER2-positive early breast cancer (eBC) These data suggest that the benefit observed with the Perjeta regimen over Herceptin and chemotherapy in the primary analysis of the trial may translate into longer-term improvements in patient outcomes The results also add to the body of evidence suggesting an association between pathological complete response (pCR) and longer-term outcomes in patients with HER2-positive eBC Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new results from the Phase II NeoSphere study. The results suggest that Perjeta® (pertuzumab) in combination with Herceptin® (trastuzumab) and docetaxel chemotherapy given prior to surgery reduced the risk of disease getting worse and increased the time people lived without their cancer returning compared to Herceptin and chemotherapy in people with HER2-positive early breast cancer (eBC). The safety profile of the Perjeta regimen was consistent with that seen in previous studies, and no new safety signals were identified. These data will be presented today at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago by Dr Luca Gianni, Medical Oncology, San Raffaele Hospital, Scientific Institute (Abstract #505). In the NeoSphere study, both progression-free survival (PFS) and disease-free survival (DFS) were evaluated at three years. The results suggest that people who received the Perjeta regimen prior to surgery were 31 percent less likely to experience disease worsening, recurrence or death (PFS HR=0.69; 95% CI, 0.34–1.40) compared to those who received Herceptin and chemotherapy.1 People treated with the Perjeta regimen were also 40 percent less likely to experience disease recurrence or death (DFS HR=0.60; 95% CI, 0.28–1.27).1 People in the NeoSphere study who were treated in the neoadjuvant setting also received a year of adjuvant.
source: Roche press release